Efficient Delivery of Therapeutic siRNA by Fe3O4 Magnetic Nanoparticles into Oral Cancer Cells
Abstract
:1. Introduction
2. Materials and Methods
2.1. Synthesis and Characterization of Nanoparticles
2.2. Gel Retardation Assay
2.3. Cell Culture
2.4. Cell Transfection
2.5. Perl’s Prussian Blue Staining
2.6. Quantitative Real-time PCR
2.7. Western Blotting
2.8. Cell Viability Assay
2.9. Transwell Migration Assay
2.10. Cell Cycle Analysis
2.11. Statistical Analysis
3. Results
3.1. Nanoparticle Characterization
3.2. Cellular Upkake of Nanoparticle/siRNA
3.3. Gene-Silencing Efficiency
3.4. Anti-Tumor Activity
4. Discussion
Author Contributions
Funding
Conflicts of Interest
References
- Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018, 68, 394–424. [Google Scholar] [CrossRef] [PubMed]
- Ferlay, J.; Colombet, M.; Soerjomataram, I.; Mathers, C.; Parkin, D.M.; Pineros, M.; Znaor, A.; Bray, F. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int. J. Cancer 2019, 144, 1941–1953. [Google Scholar] [CrossRef] [PubMed]
- Cheraghlou, S.; Schettino, A.; Zogg, C.K.; Judson, B.L. Changing prognosis of oral cancer: An analysis of survival and treatment between 1973 and 2014. Laryngoscope 2018, 128, 2762–2769. [Google Scholar] [CrossRef] [PubMed]
- Li, C.C.; Shen, Z.; Bavarian, R.; Yang, F.; Bhattacharya, A. Oral Cancer: Genetics and the Role of Precision Medicine. Dent. Clin. N. Am. 2018, 62, 29–46. [Google Scholar] [CrossRef] [PubMed]
- Marcazzan, S.; Varoni, E.M.; Blanco, E.; Lodi, G.; Ferrari, M. Nanomedicine, an emerging therapeutic strategy for oral cancer therapy. Oral Oncol. 2018, 76, 1–7. [Google Scholar] [CrossRef] [PubMed]
- Setten, R.L.; Rossi, J.J.; Han, S.P. The current state and future directions of RNAi-based therapeutics. Nat. Rev. Drug Discov. 2019, 18, 421–446. [Google Scholar] [CrossRef]
- Kim, D.H.; Rossi, J.J. Strategies for silencing human disease using RNA interference. Nat. Rev. Genet. 2007, 8, 173–184. [Google Scholar] [CrossRef]
- Hu, B.; Weng, Y.; Xia, X.H.; Liang, X.J.; Huang, Y. Clinical advances of siRNA therapeutics. J. Gene Med. 2019, 21, e3097. [Google Scholar] [CrossRef]
- Yin, H.; Kanasty, R.L.; Eltoukhy, A.A.; Vegas, A.J.; Dorkin, J.R.; Anderson, D.G. Non-viral vectors for gene-based therapy. Nat. Rev. Genet. 2014, 15, 541–555. [Google Scholar] [CrossRef]
- Dong, Y.; Siegwart, D.J.; Anderson, D.G. Strategies, design, and chemistry in siRNA delivery systems. Adv. Drug Dev. Rev. 2019. [Google Scholar] [CrossRef]
- Bochicchio, S.; Dapas, B.; Russo, I.; Ciacci, C.; Piazza, O.; De Smedt, S.; Pottie, E.; Barba, A.A.; Grassi, G. In vitro and ex vivo delivery of tailored siRNA-nanoliposomes for E2F1 silencing as a potential therapy for colorectal cancer. Int. J. Pharm. 2017, 525, 377–387. [Google Scholar] [CrossRef] [PubMed]
- Wang, R.; Degirmenci, V.; Xin, H.; Li, Y.; Wang, L.; Chen, J.; Hu, X.; Zhang, D. PEI-Coated Fe3O4 Nanoparticles Enable Efficient Delivery of Therapeutic siRNA Targeting REST into Glioblastoma Cells. Int. J. Mol. Sci. 2018, 19, 2230. [Google Scholar] [CrossRef] [PubMed]
- Zhang, D.; Wang, J.; Wang, Z.; Wang, R.; Song, L.; Zhang, T.; Lin, X.; Shi, P.; Xin, H.; Pang, X. Polyethyleneimine-Coated Fe3O4 Nanoparticles for Efficient siRNA Delivery to Human Mesenchymal Stem Cells Derived from Different Tissues. Sci. Adv. Mater. 2015, 7, 1058–1064. [Google Scholar] [CrossRef]
- Delbridge, A.R.; Grabow, S.; Strasser, A.; Vaux, D.L. Thirty years of BCL-2: Translating cell death discoveries into novel cancer therapies. Nat. Rev. Cancer 2016, 16, 99–109. [Google Scholar] [CrossRef]
- Radha, G.; Raghavan, S.C. BCL2: A promising cancer therapeutic target. Biochim. Biophys. Acta 2017, 1868, 309–314. [Google Scholar] [CrossRef]
- Knight, T.; Luedtke, D.; Edwards, H.; Taub, J.W.; Ge, Y. A delicate balance—The BCL-2 family and its role in apoptosis, oncogenesis, and cancer therapeutics. Biochem. Pharmacol. 2019, 162, 250–261. [Google Scholar] [CrossRef]
- Alam, M.; Kashyap, T.; Pramanik, K.K.; Singh, A.K.; Nagini, S.; Mishra, R. The elevated activation of NFkappaB and AP-1 is correlated with differential regulation of Bcl-2 and associated with oral squamous cell carcinoma progression and resistance. Clin. Oral Investig. 2017, 21, 2721–2731. [Google Scholar] [CrossRef]
- Xiong, L.; Tang, Y.; Liu, Z.; Dai, J.; Wang, X. BCL-2 inhibition impairs mitochondrial function and targets oral tongue squamous cell carcinoma. Springerplus 2016, 5, 1626. [Google Scholar] [CrossRef]
- Wheatley, S.P.; Altieri, D.C. Survivin at a glance. J. Cell Sci. 2019, 132. [Google Scholar] [CrossRef]
- Martinez-Garcia, D.; Manero-Ruperez, N.; Quesada, R.; Korrodi-Gregorio, L.; Soto-Cerrato, V. Therapeutic strategies involving survivin inhibition in cancer. Med. Res. Rev. 2019, 39, 887–909. [Google Scholar] [CrossRef]
- Troiano, G.; Guida, A.; Aquino, G.; Botti, G.; Losito, N.S.; Papagerakis, S.; Pedicillo, M.C.; Ionna, F.; Longo, F.; Cantile, M.; et al. Integrative Histologic and Bioinformatics Analysis of BIRC5/Survivin Expression in Oral Squamous Cell Carcinoma. Int. J. Mol. Sci. 2018, 19, 2664. [Google Scholar] [CrossRef] [PubMed]
- Calatayud, M.P.; Riggio, C.; Raffa, V.; Sanz, B.; Torres, T.E.; Ibarra, M.R.; Hoskins, C.; Cuschieri, A.; Wang, L.; Pinkernelle, J.; et al. Neuronal cells loaded with PEI-coated Fe3O4 nanoparticles for magnetically guided nerve regeneration. J. Mater. Chem. B 2013, 1, 3607–3616. [Google Scholar] [CrossRef]
- Zhang, D.; Wang, R.; Wang, Z.; Dong, J.; Shi, P.; Zhang, T.; Lin, X.; Pang, X. In Vitro Toxicity of PEI-Coated Fe3O4 Nanoparticles in HaCaT Cells. Mater. Focus 2014, 3, 145–148. [Google Scholar] [CrossRef]
- Denais, C.M.; Gilbert, R.M.; Isermann, P.; McGregor, A.L.; te Lindert, M.; Weigelin, B.; Davidson, P.M.; Friedl, P.; Wolf, K.; Lammerding, J. Nuclear envelope rupture and repair during cancer cell migration. Science 2016, 352, 353–358. [Google Scholar] [CrossRef] [PubMed]
- Gomes-da-Silva, L.C.; Fonseca, N.A.; Moura, V.; Pedroso de Lima, M.C.; Simoes, S.; Moreira, J.N. Lipid-based nanoparticles for siRNA delivery in cancer therapy: Paradigms and challenges. Acc. Chem. Res. 2012, 45, 1163–1171. [Google Scholar] [CrossRef]
- Selvam, C.; Mutisya, D.; Prakash, S.; Ranganna, K.; Thilagavathi, R. Therapeutic potential of chemically modified siRNA: Recent trends. Chem. Biol. Drug Des. 2017, 90, 665–678. [Google Scholar] [CrossRef]
- Kaur, K.; Rath, G.; Chandra, S.; Singh, R.; Goyal, A.K. Chemotherapy with si-RNA and Anti-Cancer Drugs. Curr Drug Deliv. 2018, 15, 300–311. [Google Scholar] [CrossRef]
- Maheshwari, R.; Tekade, M.; Gondaliya, P.; Kalia, K.; D’Emanuele, A.; Tekade, R.K. Recent advances in exosome-based nanovehicles as RNA interference therapeutic carriers. Nanomedicine 2017, 12, 2653–2675. [Google Scholar] [CrossRef]
- Wang, D.; Xu, X.; Zhang, K.; Sun, B.; Wang, L.; Meng, L.; Liu, Q.; Zheng, C.; Yang, B.; Sun, H. Codelivery of doxorubicin and MDR1-siRNA by mesoporous silica nanoparticles-polymerpolyethylenimine to improve oral squamous carcinoma treatment. Int. J. Nanomed. 2018, 13, 187–198. [Google Scholar] [CrossRef]
- Ma, C.; Shi, L.; Huang, Y.; Shen, L.; Peng, H.; Zhu, X.; Zhou, G. Nanoparticle delivery of Wnt-1 siRNA enhances photodynamic therapy by inhibiting epithelial-mesenchymal transition for oral cancer. Biomater. Sci. 2017, 5, 494–501. [Google Scholar] [CrossRef]
- Liu, T.; Wang, L.; Xin, H.; Jin, L.; Zhang, D. Delivery Systems for RNA Interference-Based Therapy and Their Applications Against Cancer. Sci. Adv. Mater. 2020, 12, 75–86. [Google Scholar] [CrossRef]
- Reynolds, A.; Leake, D.; Boese, Q.; Scaringe, S.; Marshall, W.S.; Khvorova, A. Rational siRNA design for RNA interference. Nat. Biotechnol. 2004, 22, 326–330. [Google Scholar] [CrossRef] [PubMed]
- Sioud, M.; Sorensen, D.R. Cationic liposome-mediated delivery of siRNAs in adult mice. Biochem. Biophys. Res. Commun. 2003, 312, 1220–1225. [Google Scholar] [CrossRef] [PubMed]
Gene | Primer Sequence | Product Length (bp) |
---|---|---|
BCL2 | forward: 5′-GATAACGGAGGCTGGGATGC-3′ | 105 |
reverse: 5′-CAGGGCCAAACTGAGCAGAG-3′ | ||
BIRC5 | forward: 5′-TGAGAACGAGCCAGACTTGG-3′ | 86 |
reverse: 5′-GTTCCTCTATGGGGTCGTCA-3′ | ||
GAPDH [13] | forward: 5′-GCACCGTCAAGGCTGAGAAC-3′ | 138 |
reverse: 5′-TGGTGAAGACGCCAGTGGA-3′ |
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Jin, L.; Wang, Q.; Chen, J.; Wang, Z.; Xin, H.; Zhang, D. Efficient Delivery of Therapeutic siRNA by Fe3O4 Magnetic Nanoparticles into Oral Cancer Cells. Pharmaceutics 2019, 11, 615. https://doi.org/10.3390/pharmaceutics11110615
Jin L, Wang Q, Chen J, Wang Z, Xin H, Zhang D. Efficient Delivery of Therapeutic siRNA by Fe3O4 Magnetic Nanoparticles into Oral Cancer Cells. Pharmaceutics. 2019; 11(11):615. https://doi.org/10.3390/pharmaceutics11110615
Chicago/Turabian StyleJin, Lili, Qiuyu Wang, Jiayu Chen, Zixiang Wang, Hongchuan Xin, and Dianbao Zhang. 2019. "Efficient Delivery of Therapeutic siRNA by Fe3O4 Magnetic Nanoparticles into Oral Cancer Cells" Pharmaceutics 11, no. 11: 615. https://doi.org/10.3390/pharmaceutics11110615